Founded in 1932, Interpharma Praha, a.s. (IPP) offers a broad range of research, development and contract manufacturing services focused on the areas of X-ray contrast media, active pharmaceutical and nutraceutical ingredients. IPP can support or lead your process development, process optimization, or process scale-up initiatives, and if desired, can support your manufacturing requirements ranging from gram scale to multi-ton commercial production quantities.
In 2008 IPP became a wholly owned subsidiary of the Japan’s Otsuka Pharmaceutical Company. Benefiting from their in-depth international pharmaceutical and regulatory experience, our senior management staff has successfully assembled a highly professional team and established a fully GMP-compliant manufacturing facility. This team of experienced professionals is dedicated to the development and manufacture of numerous APIs, intermediates, final products and innovative nutraceuticals.
What we offer
IPP targets three market segments in the global pharmaceutical industry:
- Custom Contract Manufacturing Services: IPP can supply cGMP materials from the IND stage through clinical development, market launch and post-launch commercial requirements.
- X-ray contrast media and general API manufacturing: IPP processes are guaranteed to be non-infringing, and products are supplied at competitive price levels.
- Nutraceutical ingredients: IPP offers high quality ingredient for functional supplements.
- Dermocosmetics: IPP offers the product through a unique mechanism of hair root protection.
The manufacturing site of Interpharma Praha, a.s. (IPP) is located in a residential area on the outskirts of Prague, therefore the company ensures controls are in place to minimize the influence of its manufacturing activities on the local environment. IPP continues to make significant investments in equipment and procedures to ensure no adverse impact on the environment or on the local community.
In the area of air quality Interpharma has achieved a substantial reduction in the emissions of air pollutants in recent years. A system to capture solid pollutants, hydrogen chloride and all volatile organic substances was installed. The most significant investment, and also the most important step to reduce emissions, was the construction of a catalytic oxidation unit. The capacity of this unit is 6500m3/h. It utilizes catalytic decomposition of volatile substances contained in the waste air produced by all manufacturing units on a platinum-palladium catalyst which resulted in a 90% reduction of the volatile organic substances emissions. Air emissions of Interpharma meet or exceed all local and national regulatory requirements.
The waste management in IPP is firmly established: all waste is separated and classified according to its kind and hazard class. Separated waste is handled by a specialized external company and is either recycled or disposed of according to all regulatory requirements.
Interpharma Praha constructed its own waste water treatment plant utilizing a common biological process. The sewage system was designed to separate and collect the industrial waste water, the sewage water and the rain water. The technology of the waste water treatment plant is designed to ensure full compliance, even during the maximum waste water outputs from the production plant (i.e. 20l/s, 900 m3/day, 250.000m3/year). The water protection policy is supported by the appropriate storage management of hazardous chemicals.
Finally, Interpharma is also focused on decreasing any potential environmental burden of chemical manufacturing by notable investments into environmentally-friendly technologies with lower pollutant emissions and lower production of solid and liquid wastes. This improvement has been evidenced by the results of environmental monitoring, as well as by the favorable results of the routine regulatory environmental audits.výsledky auditů z posledních let.